Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia

Area of Science:

• Metabolic research
• Endocrinology
• Pharmacology

Background:

• Peroxisome proliferator-activated receptor alpha (PPARα) agonists may improve insulin sensitivity and adiponectin levels.
• High molecular weight (HMW) adiponectin and visfatin are linked to glucose metabolism.
• PPARα agonists' effects on these adipokines and glucose metabolism warrant investigation.

Purpose of the Study:

• To investigate the effects of fenofibrate, a PPARα agonist, on lipid profiles, adipokines, and glucose metabolism in hypertriglyceridemic males.
• To assess changes in total and HMW adiponectin and visfatin levels post-fenofibrate treatment.

Main Methods:

• Eleven male subjects with hypertriglyceridemia were treated with fenofibrate for 3 months.
• Measurements included serum lipids (total cholesterol, triglyceride, HDL-C, LDL-C), fasting glucose, fasting insulin, total adiponectin, HMW adiponectin, and visfatin before and after treatment.
• Insulin sensitivity was assessed using the glucose/insulin (G/I) ratio and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).

Main Results:

• Fenofibrate significantly reduced total cholesterol, triglyceride, and LDL-C levels.
• HDL-C levels significantly increased after fenofibrate treatment.
• Serum HMW adiponectin levels increased significantly, while total adiponectin and visfatin levels remained unchanged.
• No significant changes were observed in insulin sensitivity indices (G/I ratio and HOMA-IR).

Conclusions:

• Fenofibrate treatment in hypertriglyceridemic males effectively improves lipid profiles and increases serum HMW adiponectin.
• Fenofibrate does not appear to regulate visfatin levels in this population.
• Further research is needed to determine if the fenofibrate-induced increase in HMW adiponectin translates to improved insulin sensitivity.